ZBIO: the cashflow

MyFinsight

For the quarter ending 2025-09-30, ZBIO had $71,559K increase in cash & cash equivalents over the period. -$41,125K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-51,499	-85,796
Acquired in-process research and development	5,000	-
Depreciation expense	11	35
Loss on disposal of property and equipment	0	-107
Net amortization of premiums and accretion of discounts on investments	-193	-1,317
Non-cash interest expense on royalty obligation	1,679	-
Stock-based compensation expense	7,336	11,431
Non-cash lease expense	205	446
Prepaid expenses and other assets	1,601	-802
Accounts payable	-1,954	-9,205
Accrued expenses	102	5,149
Operating lease liabilities	-211	-446
Net cash used in operating activities	-41,125	-78,794
Purchases of property and equipment	0	18
Purchases of investments	59,195	225,667
Proceeds from sales and maturities of investments	104,238	27,120
Product candidate license acquisitions	5,000	-
Net cash used in investing activities	40,043	-198,565
Payment of deferred offering costs	3,324	-
Proceeds from royalty obligation	75,000	-
Proceeds from exercise of stock options	664	1,821
Proceeds from issuance of common stock under employee stock purchase plan	276	-
Net cash provided by financing activities	72,616	1,821
Effect of exchange rate changes on cash, cash equivalents and restricted cash	25	-288
Net (decrease) increase in cash, cash equivalents and restricted cash	71,559	-275,826
Cash and cash equivalents at beginning of period	319,832	-
Cash and cash equivalents at end of period	115,565	-

Unit: Thousand (K) dollars